{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T05:03:19Z","timestamp":1789362199388,"version":"build-2803163510"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.pcad.2026.04.004","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T23:47:35Z","timestamp":1776383255000},"page":"29-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Evolution of patient characteristics and outcomes in ATTR-CM clinical trials: A systematic review"],"prefix":"10.1016","volume":"96","author":[{"given":"Ahmad","family":"Masri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Betts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Lavoie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liana","family":"Hennum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Tamby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Falvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandesh","family":"Dev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Nativi-Nicolau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pcad.2026.04.004_bb0005","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.pcad.2026.04.004_bb0010","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.pcad.2026.04.004_bb0015","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1001\/jama.2024.0442","article-title":"Cardiac amyloidosis due to transthyretin protein: a review","volume":"331","author":"Ruberg","year":"2024","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.pcad.2026.04.004_bb0020","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1002\/ehf2.13961","article-title":"Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries","volume":"9","author":"Lauppe","year":"2022","journal-title":"ESC Heart Fail"},{"issue":"1","key":"10.1016\/j.pcad.2026.04.004_bb0025","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.pcad.2026.04.004_bb0030","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.cardfail.2017.12.005","article-title":"Time course of common clinical manifestations in patients with transthyretin cardiac amyloidosis: delay from symptom onset to diagnosis","volume":"24","author":"Papoutsidakis","year":"2018","journal-title":"J Card Fail"},{"issue":"24","key":"10.1016\/j.pcad.2026.04.004_bb0035","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.pcad.2026.04.004_bb0040","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the american college of cardiology solution set oversight committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"10.1016\/j.pcad.2026.04.004_bb0045","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years","volume":"146","author":"Ioannou","year":"2022","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.pcad.2026.04.004_bb0050","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.recesp.2021.06.016","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"74","author":"Page","year":"2021","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.pcad.2026.04.004_bb0055","author":"National Institute for Health and Care Excellence"},{"key":"10.1016\/j.pcad.2026.04.004_bb0060","author":"Higgins"},{"issue":"2","key":"10.1016\/j.pcad.2026.04.004_bb0065","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s10741-021-10143-4","article-title":"The use of diflunisal for transthyretin cardiac amyloidosis: a review","volume":"27","author":"Ibrahim","year":"2022","journal-title":"Heart Fail Rev"},{"issue":"4","key":"10.1016\/j.pcad.2026.04.004_bb0070","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1136\/ejhpharm-2018-001823","article-title":"Overview of treatments used in transthyretin-related hereditary amyloidosis: a systematic review","volume":"27","author":"Cristobal Gutierrez","year":"2020","journal-title":"Eur J Hosp Pharm"},{"issue":"9","key":"10.1016\/j.pcad.2026.04.004_bb0075","article-title":"A systematic review of tafamidis in patients with transthyretin amyloid cardiomyopathy","volume":"13","author":"Singh","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.pcad.2026.04.004_bb0080","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.pcad.2026.04.004_bb0085","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pcad.2026.04.004_bb0090","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.pcad.2026.04.004_bb0095","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.pcad.2026.04.004_bb0100","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy","volume":"74","author":"Judge","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"11_Supplement","key":"10.1016\/j.pcad.2026.04.004_bb0105","article-title":"Inotersen improves quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy and cardiomyopathy: results of the phase 3 study NEURO-TTR","volume":"71","author":"Maurer","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.pcad.2026.04.004_bb0110","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/13506129.2019.1685487","article-title":"Inotersen therapy of transthyretin amyloid cardiomyopathy","volume":"27","author":"Dasgupta","year":"2020","journal-title":"Amyloid"},{"key":"10.1016\/j.pcad.2026.04.004_bb0115","series-title":"International Symposium on Amyloidosis 2022. Heidelberg, Germany","article-title":"Inotersen treatment in transthyretin amyloid cardiomyopathy results in early and sustained serum transthyretin knockdown [paper]","author":"Giblin","year":"2022"},{"key":"10.1016\/j.pcad.2026.04.004_bb0120","series-title":"International Symposium on Amyloidosis 2022. Heidelberg, Germany","article-title":"Diflunisal treatment for hereditary transthyretin amyloidosis \u2013 the Swedish DFNS-02 trial [paper]","author":"Wixner","year":"2022"},{"issue":"3","key":"10.1016\/j.pcad.2026.04.004_bb0125","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1161\/CIRCHEARTFAILURE.113.000890","article-title":"Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes","volume":"8","author":"Maurer","year":"2015","journal-title":"Circ Heart Fail"},{"issue":"suppl 1","key":"10.1016\/j.pcad.2026.04.004_bb0130","first-page":"S2","article-title":"Safety and efficacy of tafamidis in Chinese patients with transthyretin [abstract]","volume":"31","author":"Tian","year":"2024","journal-title":"Amyloid"},{"issue":"1","key":"10.1016\/j.pcad.2026.04.004_bb0135","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193","article-title":"Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy","volume":"15","author":"Elliott","year":"2022","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.pcad.2026.04.004_bb0140","doi-asserted-by":"crossref","unstructured":"Masri A, Aras M, Falk RH, et al. Long-term safety and tolerability of acoramidis (AG10) in symptomatic transthyretin amyloid cardiomyopathy: updated analysis from an ongoing phase 2 open-label extension study [paper]. In: International Symposium on Amyloidosis 2022. Heidelberg, Germany.","DOI":"10.1016\/S0735-1097(22)01218-9"},{"key":"10.1016\/j.pcad.2026.04.004_bb0145","author":"ClinicalTrials.gov"},{"issue":"4","key":"10.1016\/j.pcad.2026.04.004_bb0150","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cardfail.2022.10.013","article-title":"Primary results from Apollo-B, a phase 3 study of patisiran in patients with transthyretin-mediated amyloidosis with cardiomyopathy","volume":"29","author":"Maurer","year":"2023","journal-title":"J Card Fail"},{"issue":"11","key":"10.1016\/j.pcad.2026.04.004_bb0155","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.pcad.2026.04.004_bb0160","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.pcad.2026.04.004_bb0165","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1161\/CIRCIMAGING.112.973560","article-title":"Normal left ventricular myocardial thickness for middle-aged and older subjects with steady-state free precession cardiac magnetic resonance: the multi-ethnic study of atherosclerosis","volume":"5","author":"Kawel","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"issue":"9","key":"10.1016\/j.pcad.2026.04.004_bb0170","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.jacep.2020.04.019","article-title":"Atrial fibrillation in transthyretin cardiac amyloidosis: predictors, prevalence, and efficacy of rhythm control strategies","volume":"6","author":"Donnellan","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"issue":"4","key":"10.1016\/j.pcad.2026.04.004_bb0175","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jaccao.2024.03.007","article-title":"Atrial fibrillation as a prognostic factor for all-cause mortality in patients with transthyretin amyloid cardiomyopathy","volume":"6","author":"Witteles","year":"2024","journal-title":"JACC CardioOncol"},{"issue":"14","key":"10.1016\/j.pcad.2026.04.004_bb0180","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.jacc.2023.12.036","article-title":"Stratifying disease progression in patients with cardiac ATTR amyloidosis","volume":"83","author":"Ioannou","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.pcad.2026.04.004_bb0185","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ejhf.2198","article-title":"Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pcad.2026.04.004_bb0190","series-title":"Transthyretin Amyloid Cardiomyopathy (ATTR-CM)","author":"Jain","year":"2025"},{"issue":"1","key":"10.1016\/j.pcad.2026.04.004_bb0195","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12875-020-01252-4","article-title":"Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner","volume":"21","author":"Gertz","year":"2020","journal-title":"BMC Fam Pract"},{"issue":"6","key":"10.1016\/j.pcad.2026.04.004_bb0200","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1002\/ehf2.14517","article-title":"Detection of transthyretin amyloid cardiomyopathy by automated data extraction from electronic health records","volume":"10","author":"Moya","year":"2023","journal-title":"ESC Heart Fail"},{"issue":"3","key":"10.1016\/j.pcad.2026.04.004_bb0205","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jaccao.2024.12.005","article-title":"A multicenter study of contemporary long-term tafamidis outcomes in transthyretin amyloid cardiomyopathy","volume":"7","author":"Masri","year":"2025","journal-title":"JACC CardioOncol"},{"issue":"8","key":"10.1016\/j.pcad.2026.04.004_bb0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181373","article-title":"Community burden and prognostic impact of reduced kidney function among patients hospitalized with acute decompensated heart failure: the atherosclerosis risk in communities (ARIC) study community surveillance","volume":"12","author":"Matsushita","year":"2017","journal-title":"PloS One"},{"issue":"6","key":"10.1016\/j.pcad.2026.04.004_bb0215","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"10.1016\/j.pcad.2026.04.004_bb0220","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/0272989X12458724","article-title":"Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making"},{"key":"10.1016\/j.pcad.2026.04.004_bb0225","series-title":"Disease modifying therapies for the treatment of transthyretin amyloid cardiomyopathy. Final evidence report","author":"Wasfy","year":"2024"},{"issue":"20","key":"10.1016\/j.pcad.2026.04.004_bb0230","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.jacc.2025.03.542","article-title":"Early increase in serum transthyretin by acoramidis independently predicts improved survival in TTR amyloid cardiomyopathy","volume":"85","author":"Maurer","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"12_Supplement","key":"10.1016\/j.pcad.2026.04.004_bb0235","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/S0735-1097(25)02143-6","article-title":"Acoramidis-mediated early increase in serum transthyretin level reduces cardiovascular-related hospitalizations and mortality: insights from the ATTRibute-CM study","volume":"85","author":"Sarswat","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.pcad.2026.04.004_bb0240","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40259-023-00577-7","article-title":"RNA targeting and gene editing strategies for transthyretin amyloidosis","volume":"37","author":"Ioannou","year":"2023","journal-title":"BioDrugs"},{"issue":"10","key":"10.1016\/j.pcad.2026.04.004_bb0245","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jacc.2024.11.042","article-title":"Efficacy of acoramidis on all-cause mortality and cardiovascular hospitalization in transthyretin amyloid cardiomyopathy","volume":"85","author":"Judge","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.pcad.2026.04.004_bb0250","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy","volume":"83","author":"Porcari","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.pcad.2026.04.004_bb0255","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jchf.2025.03.017","article-title":"Current landscape of therapies for transthyretin amyloid cardiomyopathy","volume":"13","author":"Griffin","year":"2025","journal-title":"JACC Heart Fail"},{"issue":"19","key":"10.1016\/j.pcad.2026.04.004_bb0260","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2024.39.e163","article-title":"Diagnostic pitfall and clinical characteristics of variant versus wild-type transthyretin amyloid cardiomyopathy in Asian population: the Korean nationwide cohort study","volume":"39","author":"Kim","year":"2024","journal-title":"J Korean Med Sci"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062026000332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062026000332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T04:22:00Z","timestamp":1789359720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062026000332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":52,"alternative-id":["S0033062026000332"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2026.04.004","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolution of patient characteristics and outcomes in ATTR-CM clinical trials: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2026.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}